{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:40Z","timestamp":1786981540754,"version":"build-2736575974"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    N-methyl-\n                    <jats:sc>d<\/jats:sc>\n                    -aspartate (NMDA) receptor hypofunctionality is a well-studied hypothesis for schizophrenia pathophysiology, and daily dosing of the NMDA receptor co-agonist,\n                    <jats:sc>d<\/jats:sc>\n                    -serine, in clinical trials has shown positive effects in patients. Therefore, inhibition of\n                    <jats:sc>d<\/jats:sc>\n                    -amino acid oxidase (DAAO) has the potential to be a new therapeutic approach for the treatment of schizophrenia. TAK-831 (luvadaxistat), a novel, highly potent inhibitor of DAAO, significantly increases\n                    <jats:sc>d<\/jats:sc>\n                    -serine levels in the rodent brain, plasma, and cerebrospinal fluid. This study shows luvadaxistat to be efficacious in animal tests of cognition and in a translational animal model for cognitive impairment in schizophrenia. This is demonstrated when luvadaxistat is dosed alone and in conjunction with a typical antipsychotic. When dosed chronically, there is a suggestion of change in synaptic plasticity as seen by a leftward shift in the maximum efficacious dose in several studies. This is suggestive of enhanced activation of NMDA receptors in the brain and confirmed by modulation of long-term potentiation after chronic dosing. DAAO is highly expressed in the cerebellum, an area of increasing interest for schizophrenia, and luvadaxistat was shown to be efficacious in a cerebellar-dependent associative learning task. While luvadaxistat ameliorated the deficit seen in sociability in two different negative symptom tests of social interaction, it failed to show an effect in endpoints of negative symptoms in clinical trials. These results suggest that luvadaxistat potentially could be used to improve cognitive impairment in patients with schizophrenia, which is not well addressed with current antipsychotic medications.\n                  <\/jats:p>","DOI":"10.1007\/s11064-023-03956-2","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:03:07Z","timestamp":1686214987000},"page":"3027-3041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia"],"prefix":"10.1007","volume":"48","author":[{"given":"Rosa","family":"Fradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Goetghebeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Burley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Almond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Gruart i Mass\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Delgado Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear","family":"Howley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo C.","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Gaskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Serrats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceri H.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"3956_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/schbul\/sbs076","volume":"38","author":"JT Coyle","year":"2012","unstructured":"Coyle JT (2012) NMDA receptor and schizophrenia: a brief history. Schizophr Bull 38:920\u2013926","journal-title":"Schizophr Bull"},{"issue":"8","key":"3956_CR2","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/ijms18081689","volume":"18","author":"AC Yang","year":"2017","unstructured":"Yang AC, Tsai SJ (2017) New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci 18(8):1689","journal-title":"Int J Mol Sci"},{"key":"3956_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nyas.12547","volume":"1338","author":"W Hu","year":"2015","unstructured":"Hu W, MacDonald ML, Elswick DE, Sweet RA (2015) The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci 1338:38\u201357","journal-title":"Ann N Y Acad Sci"},{"key":"3956_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/00001756-199504190-00011","volume":"6","author":"AC Lahti","year":"1995","unstructured":"Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6:869\u2013872","journal-title":"NeuroReport"},{"key":"3956_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","volume":"13","author":"AC Lahti","year":"1995","unstructured":"Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9\u201319","journal-title":"Neuropsychopharmacology"},{"key":"3956_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/285355a0","volume":"285","author":"SH Snyder","year":"1980","unstructured":"Snyder SH (1980) Phencyclidine. Nature 285:355\u2013356","journal-title":"Nature"},{"key":"3956_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biopsych.2014.07.011","volume":"77","author":"J Hall","year":"2015","unstructured":"Hall J, Trent S, Thomas KL, O\u2019Donovan MC, Owen MJ (2015) Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biol Psychiatry 77:52\u201358","journal-title":"Biol Psychiatry"},{"key":"3956_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiat 71:637\u2013646","journal-title":"JAMA Psychiat"},{"key":"3956_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","volume":"151","author":"DC Javitt","year":"1994","unstructured":"Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234\u20131236","journal-title":"Am J Psychiatry"},{"key":"3956_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"SF Traynelis","year":"2010","unstructured":"Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405\u2013496","journal-title":"Pharmacol Rev"},{"key":"3956_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.coph.2014.12.004","volume":"20","author":"DT Balu","year":"2015","unstructured":"Balu DT, Coyle JT (2015) The NMDA receptor \u201cglycine modulatory site\u201d in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol 20:109\u2013115","journal-title":"Curr Opin Pharmacol"},{"key":"3956_CR12","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1073\/pnas.97.9.4926","volume":"97","author":"JP Mothet","year":"2000","unstructured":"Mothet JP, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, Rogawski MA, Snyder SH (2000) D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 97:4926\u20134931","journal-title":"Proc Natl Acad Sci USA"},{"key":"3956_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.tins.2016.09.007","volume":"39","author":"H Wolosker","year":"2016","unstructured":"Wolosker H, Balu DT, Coyle JT (2016) The rise and fall of the d-serine-mediated gliotransmission hypothesis. Trends Neurosci 39:712\u2013721","journal-title":"Trends Neurosci"},{"key":"3956_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fpsyt.2019.00025","volume":"10","author":"MB MacKay","year":"2019","unstructured":"MacKay MB, Kravtsenyuk M, Thomas R, Mitchell ND, Dursun SM, Baker GB (2019) D-Serine: potential therapeutic agent and\/or biomarker in schizophrenia and depression? Front Psychiatry 10:25","journal-title":"Front Psychiatry"},{"key":"3956_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1523\/JNEUROSCI.08-01-00185.1988","volume":"8","author":"DW Choi","year":"1988","unstructured":"Choi DW, Koh JY, Peters S (1988) Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci 8:185\u2013196","journal-title":"J Neurosci"},{"key":"3956_CR16","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nrd3893","volume":"12","author":"RJ Harvey","year":"2013","unstructured":"Harvey RJ, Yee BK (2013) Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 12:866\u2013885","journal-title":"Nat Rev Drug Discov"},{"key":"3956_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2016.10.027","volume":"182","author":"E Dunayevich","year":"2017","unstructured":"Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S (2017) Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res 182:90\u201397","journal-title":"Schizophr Res"},{"key":"3956_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","volume":"82","author":"D Bugarski-Kirola","year":"2017","unstructured":"Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR (2017) Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry 82:8\u201316","journal-title":"Biol Psychiatry"},{"key":"3956_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1046\/j.1471-4159.1995.65010454.x","volume":"65","author":"T Matsui","year":"1995","unstructured":"Matsui T, Sekiguchi M, Hashimoto A, Tomita U, Nishikawa T, Wada K (1995) Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. J Neurochem 65:454\u2013458","journal-title":"J Neurochem"},{"key":"3956_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383\u2013400","journal-title":"Nat Rev Neurosci"},{"key":"3956_CR21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1124\/mol.107.040071","volume":"72","author":"C Madry","year":"2007","unstructured":"Madry C, Mesic I, Betz H, Laube B (2007) The N-terminal domains of both NR1 and NR2 subunits determine allosteric Zn2+ inhibition and glycine affinity of N-methyl-D-aspartate receptors. Mol Pharmacol 72:1535\u20131544","journal-title":"Mol Pharmacol"},{"key":"3956_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2012.06.029","volume":"150","author":"T Papouin","year":"2012","unstructured":"Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet JP, Oliet SH (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150:633\u2013646","journal-title":"Cell"},{"key":"3956_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nn.2791","volume":"14","author":"W Kakegawa","year":"2011","unstructured":"Kakegawa W, Miyoshi Y, Hamase K, Matsuda S, Matsuda K, Kohda K, Emi K, Motohashi J, Konno R, Zaitsu K, Yuzaki M (2011) D-serine regulates cerebellar LTD and motor coordination through the delta2 glutamate receptor. Nat Neurosci 14:603\u2013611","journal-title":"Nat Neurosci"},{"key":"3956_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2017.02.027","volume":"191","author":"JT Kantrowitz","year":"2018","unstructured":"Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC (2018) Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: correlation with symptoms. Schizophr Res 191:70\u201379","journal-title":"Schizophr Res"},{"key":"3956_CR25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","volume":"60","author":"K Hashimoto","year":"2003","unstructured":"Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572\u2013576","journal-title":"Arch Gen Psychiatry"},{"key":"3956_CR26","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","volume":"29","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M (2005) Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29:767\u2013769","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3956_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.8","volume":"6","author":"K Hashimoto","year":"2016","unstructured":"Hashimoto K, Bruno D, Nierenberg J, Marmar CR, Zetterberg H, Blennow K, Pomara N (2016) Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Transl Psychiatry 6:e744","journal-title":"Transl Psychiatry"},{"key":"3956_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2006.10.010","volume":"90","author":"I Bendikov","year":"2007","unstructured":"Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G (2007) A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res 90:41\u201351","journal-title":"Schizophr Res"},{"key":"3956_CR29","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.pnpbp.2008.07.022","volume":"32","author":"T Ohnuma","year":"2008","unstructured":"Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, Kida S, Shibata N, Suzuki T, Arai H (2008) Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 32:1905\u20131912","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3956_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2012.09.014","volume":"142","author":"MA Calcia","year":"2012","unstructured":"Calcia MA, Madeira C, Alheira FV, Silva TC, Tannos FM, Vargas-Lopes C, Goldenstein N, Brasil MA, Ferreira ST, Panizzutti R (2012) Plasma levels of D-serine in Brazilian individuals with schizophrenia. Schizophr Res 142:83\u201387","journal-title":"Schizophr Res"},{"key":"3956_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.schres.2010.05.012","volume":"121","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D\u2019Souza C, Saksa J, Woods SW, Javitt DC (2010) High dose D-serine in the treatment of schizophrenia. Schizophr Res 121:125\u2013130","journal-title":"Schizophr Res"},{"key":"3956_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S2215-0366(15)00098-X","volume":"2","author":"JT Kantrowitz","year":"2015","unstructured":"Kantrowitz JT, Woods SW, Petkova E, Cornblatt B, Corcoran CM, Chen H, Silipo G, Javitt DC (2015) D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry 2:403\u2013412","journal-title":"Lancet Psychiatry"},{"key":"3956_CR33","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0006-3223(98)00279-0","volume":"44","author":"G Tsai","year":"1998","unstructured":"Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998) D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081\u20131089","journal-title":"Biol Psychiatry"},{"key":"3956_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jpba.2018.09.026","volume":"162","author":"H Hasegawa","year":"2019","unstructured":"Hasegawa H, Masuda N, Natori H, Shinohara Y, Ichida K (2019) Pharmacokinetics and toxicokinetics of d-serine in rats. J Pharm Biomed Anal 162:264\u2013271","journal-title":"J Pharm Biomed Anal"},{"key":"3956_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/NDT.S234371","volume":"16","author":"CH Lin","year":"2020","unstructured":"Lin CH, Yang HT, Chen PK, Wang SH, Lane HY (2020) Precision medicine of sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD). Neuropsychiatr Dis Treat 16:509\u2013518","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3956_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.mcn.2006.05.003","volume":"32","author":"SL Almond","year":"2006","unstructured":"Almond SL, Fradley RL, Armstrong EJ, Heavens RB, Rutter AR, Newman RJ, Chiu CS, Konno R, Hutson PH, Brandon NJ (2006) Behavioral and biochemical characterization of a mutant mouse strain lacking D-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 32:324\u2013334","journal-title":"Mol Cell Neurosci"},{"key":"3956_CR37","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11095-020-02893-x","volume":"37","author":"T Yoneyama","year":"2020","unstructured":"Yoneyama T, Sato S, Sykes A, Fradley R, Stafford S, Bechar S, Howley E, Patel T, Tagawa Y, Moriwaki T, Asahi S (2020) Mechanistic multilayer quantitative model for nonlinear pharmacokinetics, target occupancy and pharmacodynamics (PK\/TO\/PD) relationship of D-amino acid oxidase inhibitor, TAK-831 in mice. Pharm Res 37:164","journal-title":"Pharm Res"},{"key":"3956_CR38","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s11064-017-2367-9","volume":"42","author":"E Howley","year":"2017","unstructured":"Howley E, Bestwick M, Fradley R, Harrison H, Leveridge M, Okada K, Fieldhouse C, Farnaby W, Canning H, Sykes AP, Merchant K, Hazel K, Kerr C, Kinsella N, Walsh L, Livermore DG, Hoffman I, Ellery J, Mitchell P, Patel T, Carlton M, Barnes M, Miller DJ (2017) Assessment of the target engagement and D-serine biomarker profiles of the D-amino acid oxidase inhibitors sodium benzoate and PGM030756. Neurochem Res 42:3279\u20133288","journal-title":"Neurochem Res"},{"key":"3956_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/1087057106288181","volume":"11","author":"PE Brandish","year":"2006","unstructured":"Brandish PE, Chiu CS, Schneeweis J, Brandon NJ, Leech CL, Kornienko O, Scolnick EM, Strulovici B, Zheng W (2006) A cell-based ultra-high-throughput screening assay for identifying inhibitors of D-amino acid oxidase. J Biomol Screen 11:481\u2013487","journal-title":"J Biomol Screen"},{"key":"3956_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbr.2007.12.029","volume":"189","author":"SL McLean","year":"2008","unstructured":"McLean SL, Beck JP, Woolley ML, Neill JC (2008) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152\u2013158","journal-title":"Behav Brain Res"},{"key":"3956_CR41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1177\/0269881111431747","volume":"26","author":"SL McLean","year":"2012","unstructured":"McLean SL, Idris NF, Grayson B, Gendle DF, Mackie C, Lesage AS, Pemberton DJ, Neill JC (2012) PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol 26:1265\u20131270","journal-title":"J Psychopharmacol"},{"key":"3956_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419\u2013432","journal-title":"Pharmacol Ther"},{"key":"3956_CR43","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1523\/JNEUROSCI.2834-05.2006","volume":"26","author":"A Gruart","year":"2006","unstructured":"Gruart A, Munoz MD, Delgado-Garcia JM (2006) Involvement of the CA3-CA1 synapse in the acquisition of associative learning in behaving mice. J Neurosci 26:1077\u20131087","journal-title":"J Neurosci"},{"key":"3956_CR44","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0068-22.2022","author":"H Okamura","year":"2022","unstructured":"Okamura H, Yasugaki S, Suzuki-Abe H, Arai Y, Sakurai K, Yanagisawa M, Takizawa H, Hayashi Y (2022) Long-term effects of repeated social defeat stress on brain activity during social interaction in BALB\/c mice. eNeuro. https:\/\/doi.org\/10.1523\/ENEURO.0068-22.2022","journal-title":"eNeuro"},{"key":"3956_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00213-008-1171-2","volume":"202","author":"V Pascoli","year":"2009","unstructured":"Pascoli V, Boer-Saccomani C, Hermant JF (2009) H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval. Psychopharmacology 202:141\u2013152","journal-title":"Psychopharmacology"},{"key":"3956_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.neuropharm.2011.06.029","volume":"61","author":"CA Strick","year":"2011","unstructured":"Strick CA, Li C, Scott L, Harvey B, Hajos M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD 3rd, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ (2011) Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Neuropharmacology 61:1001\u20131015","journal-title":"Neuropharmacology"},{"key":"3956_CR47","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1038\/nprot.2013.155","volume":"8","author":"M Leger","year":"2013","unstructured":"Leger M, Quiedeville A, Bouet V, Haelewyn B, Boulouard M, Schumann-Bard P, Freret T (2013) Object recognition test in mice. Nat Protoc 8:2531\u20132537","journal-title":"Nat Protoc"},{"key":"3956_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2203\/dose-response.10-017.Mair","volume":"9","author":"RG Mair","year":"2011","unstructured":"Mair RG, Onos KD, Hembrook JR (2011) Cognitive activation by central thalamic stimulation: the yerkes-dodson law revisited. Dose Response 9:313\u2013331","journal-title":"Dose Response"},{"key":"3956_CR49","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1093\/cercor\/bhn008","volume":"18","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, Gong N, Wang W, Xu L, Xu TL (2008) Bell-shaped D-serine actions on hippocampal long-term depression and spatial memory retrieval. Cereb Cortex 18:2391\u20132401","journal-title":"Cereb Cortex"},{"key":"3956_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.7","volume":"1","author":"SC Hopkins","year":"2013","unstructured":"Hopkins SC, Campbell UC, Heffernan ML, Spear KL, Jeggo RD, Spanswick DC, Varney MA, Large TH (2013) Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo. Pharmacol Res Perspect 1:e00007","journal-title":"Pharmacol Res Perspect"},{"key":"3956_CR51","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1093\/brain\/aww262","volume":"139","author":"JT Kantrowitz","year":"2016","unstructured":"Kantrowitz JT, Epstein ML, Beggel O, Rohrig S, Lehrfeld JM, Revheim N, Lehrfeld NP, Reep J, Parker E, Silipo G, Ahissar M, Javitt DC (2016) Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. Brain 139:3281\u20133295","journal-title":"Brain"},{"key":"3956_CR52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.psychres.2004.09.007","volume":"129","author":"PJ Tyson","year":"2004","unstructured":"Tyson PJ, Laws KR, Roberts KH, Mortimer AM (2004) Stability of set-shifting and planning abilities in patients with schizophrenia. Psychiatry Res 129:229\u2013239","journal-title":"Psychiatry Res"},{"key":"3956_CR53","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.euroneuro.2013.09.011","volume":"24","author":"JC Neill","year":"2014","unstructured":"Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM (2014) Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur Neuropsychopharmacol 24:822\u2013835","journal-title":"Eur Neuropsychopharmacol"},{"key":"3956_CR54","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/schbul\/sbt112","volume":"40","author":"AR Bolbecker","year":"2014","unstructured":"Bolbecker AR, Kent JS, Petersen IT, Klaunig MJ, Forsyth JK, Howell JM, Westfall DR, O\u2019Donnell BF, Hetrick WP (2014) Impaired cerebellar-dependent eyeblink conditioning in first-degree relatives of individuals with schizophrenia. Schizophr Bull 40:1001\u20131010","journal-title":"Schizophr Bull"},{"key":"3956_CR55","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1523\/JNEUROSCI.2178-09.2009","volume":"29","author":"R Sanchez-Campusano","year":"2009","unstructured":"Sanchez-Campusano R, Gruart A, Delgado-Garcia JM (2009) Dynamic associations in the cerebellar-motoneuron network during motor learning. J Neurosci 29:10750\u201310763","journal-title":"J Neurosci"},{"key":"3956_CR56","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/ncomms3258","volume":"4","author":"MT Hasan","year":"2013","unstructured":"Hasan MT, Hernandez-Gonzalez S, Dogbevia G, Trevino M, Bertocchi I, Gruart A, Delgado-Garcia JM (2013) Role of motor cortex NMDA receptors in learning-dependent synaptic plasticity of behaving mice. Nat Commun 4:2258","journal-title":"Nat Commun"},{"key":"3956_CR57","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1101\/lm.59603","volume":"10","author":"KM Christian","year":"2003","unstructured":"Christian KM, Thompson RF (2003) Neural substrates of eyeblink conditioning: acquisition and retention. Learn Mem 10:427\u2013455","journal-title":"Learn Mem"},{"key":"3956_CR58","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41386-023-01560-0","volume":"48","author":"P O'Donnell","year":"2023","unstructured":"O\u2019Donnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, Lu H, Xu L, Wendland JR, Dunayevich E, Buhl DL, Litman R, Hetrick WP, Hong LE, Rosen LB (2023) The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacology 48:1052\u20131059","journal-title":"Neuropsychopharmacology"},{"key":"3956_CR59","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.biopsych.2013.08.010","volume":"75","author":"CH Lin","year":"2014","unstructured":"Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, Lane HY (2014) Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 75:678\u2013685","journal-title":"Biol Psychiatry"},{"key":"3956_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbr.2006.06.025","volume":"176","author":"ES Brodkin","year":"2007","unstructured":"Brodkin ES (2007) BALB\/c mice: low sociability and other phenotypes that may be relevant to autism. Behav Brain Res 176:53\u201365","journal-title":"Behav Brain Res"},{"key":"3956_CR61","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbi.2014.06.013","volume":"42","author":"S Missault","year":"2014","unstructured":"Missault S, Van den Eynde K, Vanden Berghe W, Fransen E, Weeren A, Timmermans JP, Kumar-Singh S, Dedeurwaerdere S (2014) The risk for behavioural deficits is determined by the maternal immune response to prenatal immune challenge in a neurodevelopmental model. Brain Behav Immun 42:138\u2013146","journal-title":"Brain Behav Immun"},{"key":"3956_CR62","first-page":"16","volume":"6","author":"M D'Ascenzo","year":"2014","unstructured":"D\u2019Ascenzo M, Podda MV, Grassi C (2014) The role of D-serine as co-agonist of NMDA receptors in the nucleus accumbens: relevance to cocaine addiction. Front Synaptic Neurosci 6:16","journal-title":"Front Synaptic Neurosci"},{"key":"3956_CR63","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nn1086","volume":"6","author":"H Hirai","year":"2003","unstructured":"Hirai H, Launey T, Mikawa S, Torashima T, Yanagihara D, Kasaura T, Miyamoto A, Yuzaki M (2003) New role of delta2-glutamate receptors in AMPA receptor trafficking and cerebellar function. Nat Neurosci 6:869\u2013876","journal-title":"Nat Neurosci"},{"key":"3956_CR64","first-page":"374","volume":"46","author":"V Murthy","year":"2021","unstructured":"Murthy V, Hanson E, DeMartinis N, Asgharnejad M, Dong C, Evans R, Ge T, Dunayevich E, Singh J, Ratti E, Galderisi S (2021) Luvadaxistat, an investigational D-amino acid oxidase inhibitor, was associated with signals of efficacy in cognitive impairment associated with schizophrenia but not negative symptoms: results from the interact study. Neuropsychopharmacology 46:374\u2013375","journal-title":"Neuropsychopharmacology"},{"key":"3956_CR65","first-page":"348","volume":"46","author":"P O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell P, Dong C, Murthy V, Asgharnejad M, Du X, Summerfelt A, Wendland J, Dunayevich E, Litman R, Hetrick W, Hong E, Rosen L (2021) Luvadaxistat, a D-amino acid oxidase inhibitor, improves mismatch negativity in patients with schizophrenia. Neuropsychopharmacology 46:348","journal-title":"Neuropsychopharmacology"}],"updated-by":[{"DOI":"10.1007\/s11064-023-03987-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000}}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-023-03956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11064-023-03956-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-023-03956-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T17:01:59Z","timestamp":1693501319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11064-023-03956-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["3956"],"URL":"https:\/\/doi.org\/10.1007\/s11064-023-03956-2","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11064-023-03987-9","URL":"https:\/\/doi.org\/10.1007\/s11064-023-03987-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RF, PGo, DM, RB, SA, BZ, EH, PGa, MC, IG, JS are former employees of Takeda Pharmaceuticals, and CHD is a current employee of Takeda Pharmaceuticals. The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable as this study did not involve human participants, their data or biological material.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable as this study did not involve human participants, their data or biological material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}